Lenigron

Timolol and Bimatoprost, the active ingredients in Lenigron, are a beta‑blocker and a prostaglandin analog presented as eye drops for ocular use. They are indicated for the management of primary open‑angle glaucoma and ocular hypertension, helping to lower intra‑ocular pressure and protect the optic nerve. GNH USA supplies Lenigron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenigron is used in ophthalmology to control intra‑ocular pressure in glaucoma‑related conditions. - Primary open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic‑nerve damage. - Ocular hypertension: reduces pressure to decrease the risk of progression to glaucoma. - Secondary open‑angle glaucoma: assists in achieving target pressure when other therapies are insufficient.

Lenigron may cause ocular and systemic adverse reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation: burning or stinging sensation. - Blurred vision: temporary visual disturbance. - Eyelash growth: increased length and thickness. - Darkening of iris: gradual pigmentation change. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Increased intra‑ocular pressure: paradoxical rise requiring medical attention. - Persistent eye pain: may indicate corneal involvement. - Corneal edema: swelling of the cornea affecting vision. - Uveitis: inflammation of the uveal tract. - Systemic beta‑blocker effects: bradycardia, hypotension, or bronchospasm.

Before prescribing Lenigron, clinicians should consider patient‑specific factors and monitor for adverse events. - Cardiovascular assessment: evaluate for bradycardia or heart block. - Respiratory status: avoid in patients with asthma or severe COPD. - Intra‑ocular pressure monitoring: check pressure after initiation and periodically. - Concurrent ocular surgery: discontinue before and after procedures as advised. - Use with other beta‑blockers: monitor for additive systemic effects. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Lenigron can interact with other medications that affect ocular pressure or systemic beta‑adrenergic activity.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol): may cause excessive bradycardia. - Other ocular beta‑blocker drops: risk of over‑suppression of aqueous production. - Topical adrenergic agonists (e.g., phenylephrine): may reduce the IOP‑lowering effect.

Moderate Interactions (Monitor Closely):\n- Carbonic anhydrase inhibitor eye drops: additive IOP‑lowering effect, monitor pressure. - Topical corticosteroids: may increase risk of cataract or glaucoma. - Antihistamine eye drops: possible reduced efficacy of prostaglandin component.